SecBot SecBot
8-K ·Filed Jun 10, 2026

RDNT

RadNet, Inc.
NEUTRAL
Impact 5/10
Horizonweeks Processed5mo ago SEC0001683168-26-004716
8-K material event: Items 1.01
Actionable Insight • Neutral

The upsized facility, lower spread, and stated acquisition intent signal management's confidence in deploying capital for M&A. Monitor for accretive tuck-in acquisitions and organic growth announcements. The rate reduction marginally improves net income, but higher debt load increases leverage.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$58.20
T+0 close · Jun 10, 2026 · via day close
Latest settled
+26.65%
T+60 · $73.71
Vs SPY
+22.25%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 11 $58.20entry
  2. T+1 · 5mo ago −2.56%α −3.10% · $56.71
  3. T+5 · 5mo ago −9.24%α −9.68% · $52.82
  4. T+20 · 4mo ago +13.30%α +11.41% · $65.94
  5. T+60 · 2mo ago +26.65%α +22.25% · $73.71
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

RadNet upsized its term loan by $250M to $250.0M through Incremental Amendment No. 3 to its Credit & Guaranty Agreement, while simultaneously refinancing the existing $958.7M term loan balance. The incremental term loan proceeds are earmarked for future acquisitions, organic expansion, health system partnerships, and general corporate purposes. Interest rates on both the term loan and the undrawn $282M revolver were reduced by 0.25%, providing a modest financial benefit.

Key Financial Metrics

Deal Type
credit_facility

Key Facts

  • Added $250.0M in incremental term loan commitments (2026 Incremental Term Loan) to existing credit facility
  • Refinanced $958.7M of existing term loans (2026 Refinancing Term Loans) on same terms
  • Quarterly principal payment increased to ~$3.1M from ~$2.4M per quarter
  • Interest rate on term loan reduced by 0.25% to Term SOFR + 2.00% or ABR + 1.00%
  • Interest rate on existing $282M undrawn revolver also reduced by 0.25%
  • Maturity date of all term loans is April 18, 2031
  • Proceeds earmarked for future acquisitions, organic expansion, health system partnerships, and general corporate purposes

Financial Impact

Annual interest savings of approximately $3.0M based on ~$1.2B total term debt outstanding and 0.25% rate reduction; $250M incremental debt capacity added

interest expensetotal debtleverageliquidity

Risk Factors

  • $250M incremental debt adds leverage, potentially pressuring credit ratios
  • Higher quarterly amortization ($3.1M vs $2.4M) increases mandatory cash outflow
  • Proceeds earmarked for acquisitions carry execution and integration risk
  • Company's ability to grow EBITDA to offset higher debt service is unproven

Market Snapshot

Exchange
Nasdaq
Sector
Services-Medical Laboratories
Analyst Consensus
93% bullish (14 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001683168-26-004716
Document: 0001683168-26-004716-index.html0001683168-26-004716
Document: 0001683168-26-004716.txt0001683168-26-004716

US Market Status

Market Closed · Opens Wed (13h 26m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 10, 2026